Dataset related to article: Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Systemic inflammation is associated with increased aggressiveness of breast cancer and can contribute to decreased activity of neoadjuvant treatments. Biomarkers of systemic inflammation are easily obtained from routine blood count and are highly cost-effective, having great potential to steer cancer prognosis in clinical practice. In our study we tested the hypothesis that high values of these biomarkers might have an effect on clinical outcomes in a population of patients treated with neoadjuvant chemotherapy for breast cancer. Results of our study, together with data from the literature, hint at a possible role of inflammatory markers in the diagnostic and therapeutic algorithm of breast cancer, where specific pre-operative blood cell ratios could be used in combination with biological and clinical factors to tailor adjuvant therapy.